Sharp Therapeutics Corp. is a biotechnology company focused on developing small-molecule therapeutics for genetic diseases. As a pre-clinical stage organization, it specializes in restoring or enhancing the function of mutated proteins, targeting conditions caused by hereditary defects. The company leverages advanced technologies, including high-throughput screening, computational modeling, and proprietary discovery platforms such as "Disco," to accelerate the identification and optimization of drug candidates. Sharp Therapeutics has programs addressing diseases with high unmet needs, such as Gaucher’s Disease, Familial Frontotemporal Dementia, and Niemann-Pick Type-C. By offering orally administered small-molecule treatments, the company aims to provide more accessible alternatives to conventional therapies like biologics and gene therapies. Operating from Pittsburgh, Pennsylvania, and Toronto, Ontario, Sharp Therapeutics holds a strategic role in advancing innovative solutions within the field of genetic medicine, with a clear emphasis on rapid development and translational potential for patients and healthcare systems alike.